Selectivity of melaninized nigra-striatal dopamine neurons to degeneration in Parkinson's disease may depend on iron-melanin interaction
- PMID: 2193109
- DOI: 10.1007/978-3-7091-9050-0_24
Selectivity of melaninized nigra-striatal dopamine neurons to degeneration in Parkinson's disease may depend on iron-melanin interaction
Abstract
The recent studies on the chemical pathology of Parkinson's disease show selective increases of iron and lipid peroxidation and decreased glutathione (GSH) oxidizing capacity in the substantia nigra (SN). These changes are indicative of oxidative stress, possibly due to the accumulation of iron in the SN. It is the melaninized dopamine neurons that are vunerable to degeneration. The investigation of the interaction of iron with dopamine melanin demonstrates the presence of two relatively high affinity binding sites for 59Fe3+ on dopamine melanin. Interaction of Fe3+ with dopamine melanin results in potentiation of lipid peroxidation of rat cerebral cortex as compared to that induced by Fe3+. Only compounds with the ability to chelate iron are able to inhibit the binding of Fe3+ to melanin and the resultant lipid peroxidation. Therapeutic use of iron chelators, with the ability of crossing the blood brain barrier, as agents for retarding the oxidative stress and Parkinson's disease is envisaged.
Similar articles
-
Iron-melanin interaction and lipid peroxidation: implications for Parkinson's disease.J Neurochem. 1991 Nov;57(5):1609-14. doi: 10.1111/j.1471-4159.1991.tb06358.x. J Neurochem. 1991. PMID: 1919577
-
Is Parkinson's disease a progressive siderosis of substantia nigra resulting in iron and melanin induced neurodegeneration?Acta Neurol Scand Suppl. 1989;126:47-54. doi: 10.1111/j.1600-0404.1989.tb01782.x. Acta Neurol Scand Suppl. 1989. PMID: 2618593
-
Role of iron and iron chelation in dopaminergic-induced neurodegeneration: implication for Parkinson's disease.Ann Neurol. 1992;32 Suppl:S105-10. doi: 10.1002/ana.410320718. Ann Neurol. 1992. PMID: 1510367 Review.
-
Iron, melanin and dopamine interaction: relevance to Parkinson's disease.Prog Neuropsychopharmacol Biol Psychiatry. 1993 Jan;17(1):139-50. doi: 10.1016/0278-5846(93)90038-t. Prog Neuropsychopharmacol Biol Psychiatry. 1993. PMID: 8416600
-
Oxidative stress: a role in the pathogenesis of Parkinson's disease.J Neural Transm Suppl. 1990;29:241-9. doi: 10.1007/978-3-7091-9050-0_23. J Neural Transm Suppl. 1990. PMID: 2193108 Review.
Cited by
-
The neurochemical and behavioral effects of the novel cholinesterase-monoamine oxidase inhibitor, ladostigil, in response to L-dopa and L-tryptophan, in rats.Br J Pharmacol. 2005 Oct;146(4):553-60. doi: 10.1038/sj.bjp.0706355. Br J Pharmacol. 2005. PMID: 16086033 Free PMC article.
-
The role of tyrosine hydroxylase as a key player in neuromelanin synthesis and the association of neuromelanin with Parkinson's disease.J Neural Transm (Vienna). 2023 May;130(5):611-625. doi: 10.1007/s00702-023-02617-6. Epub 2023 Mar 20. J Neural Transm (Vienna). 2023. PMID: 36939908 Free PMC article. Review.
-
Postencephalitic Parkinsonism: Unique Pathological and Clinical Features-Preliminary Data.Cells. 2024 Sep 10;13(18):1511. doi: 10.3390/cells13181511. Cells. 2024. PMID: 39329695 Free PMC article.
-
Functional effects of neuromelanin and synthetic melanin in model systems.J Neural Transm (Vienna). 2006 Jun;113(6):751-6. doi: 10.1007/s00702-006-0450-5. Epub 2006 May 5. J Neural Transm (Vienna). 2006. PMID: 16755379 Review.
-
Neuromelanin and its interaction with iron as a potential risk factor for dopaminergic neurodegeneration underlying Parkinson's disease.Neurotox Res. 2003;5(1-2):35-44. doi: 10.1007/BF03033371. Neurotox Res. 2003. PMID: 12832223 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources
Medical